Poxel's Anti-diabetic Imeglimin Shows Significant Clinical Benefits in Type 2

Poxel's Anti-diabetic Imeglimin Shows Significant Clinical Benefits in Type 2
Phase II study achieved primary and secondary endpoints; Imeglimin brings incremental efficacy on top of sitagliptin; and is safe and well tolerated. Lyon, France, 5 November 2012, – Poxel SA today announced that in a Phase II study Imeglimin, a novel …

Full News here – Read more on Reuters

Leave a Reply